[go: up one dir, main page]

MX2022000050A - Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet). - Google Patents

Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).

Info

Publication number
MX2022000050A
MX2022000050A MX2022000050A MX2022000050A MX2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A
Authority
MX
Mexico
Prior art keywords
bet
extraterminal
heterocyclic compounds
bromodomain inhibitors
inhibitors
Prior art date
Application number
MX2022000050A
Other languages
English (en)
Inventor
Sarvajit Chakravarty
Son Minh Pham
Jiyun Chen
Jayakanth Kankanala
Anup Barde
Anjan Kumar Nayak
Jeremy D Pettigrew
Chris P Miller
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of MX2022000050A publication Critical patent/MX2022000050A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan nuevos inhibidores de bromodominio y dominio extraterminal (BET) y métodos terapéuticos para tratar afecciones y enfermedades utilizando estos nuevos inhibidores de BET.
MX2022000050A 2019-07-02 2020-07-01 Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet). MX2022000050A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870020P 2019-07-02 2019-07-02
US202063017547P 2020-04-29 2020-04-29
PCT/US2020/040566 WO2021003310A1 (en) 2019-07-02 2020-07-01 Heterocyclic compounds as bet inhibitors

Publications (1)

Publication Number Publication Date
MX2022000050A true MX2022000050A (es) 2022-05-24

Family

ID=74065335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000050A MX2022000050A (es) 2019-07-02 2020-07-01 Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).

Country Status (11)

Country Link
US (3) US11584756B2 (es)
EP (1) EP3997070A4 (es)
JP (1) JP7465945B2 (es)
KR (1) KR102677015B1 (es)
CN (1) CN114286818B (es)
AU (1) AU2020299592A1 (es)
CA (1) CA3145827A1 (es)
CL (1) CL2021003513A1 (es)
IL (1) IL289439B1 (es)
MX (1) MX2022000050A (es)
WO (1) WO2021003310A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112424200B (zh) * 2018-07-25 2022-09-20 正大天晴药业集团股份有限公司 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US11584756B2 (en) * 2019-07-02 2023-02-21 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
EP4143166A4 (en) * 2020-04-29 2024-10-30 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
MX2024000238A (es) 2021-06-29 2024-01-30 Tay Therapeutics Ltd Derivados de pirrolopiridona utiles en el tratamiento del cancer.
CN116135858B (zh) * 2021-11-16 2025-04-01 中国科学院广州生物医药与健康研究院 一种呋喃并吡啶酮类化合物及其应用
MX2024008474A (es) * 2022-01-06 2024-07-12 Design Therapeutics Inc Compuestos y metodos para tratar la ataxia de friedreich.
CN114907335A (zh) * 2022-02-25 2022-08-16 陕西维世诺新材料有限公司 2-（苯并噻吩-2-基）苯并[d]惡唑衍生物、制备方法及应用
CN115028646B (zh) * 2022-05-31 2023-06-30 山东第一医科大学(山东省医学科学院) 一种含氮杂环类化合物、制备方法及在抗肿瘤制剂中的应用
TW202440098A (zh) * 2022-12-22 2024-10-16 美商諾維雪碧歐公司 使用bet抑制劑之癌症組合療法
WO2025049339A2 (en) * 2023-08-25 2025-03-06 Nuvation Bio Inc. Crystalline forms of a bet inhibitor

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
US20040067955A1 (en) 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MX2008015662A (es) 2006-06-08 2009-01-12 Lilly Co Eli Nuevos receptores antagonistas de la hormona concentradora de melanina (mch).
EP2214667A2 (en) 2007-10-22 2010-08-11 Angion Biomedica Corp. Small molecule inhibitors of parp activity
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US9663533B2 (en) 2012-11-14 2017-05-30 Glaxosmithkline Llc Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
JP2016512524A (ja) 2013-03-11 2016-04-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
US9675697B2 (en) 2013-03-11 2017-06-13 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
KR102224992B1 (ko) 2013-03-12 2021-03-10 애브비 인코포레이티드 테트라사이클릭 브로모도메인 억제제
JP6280573B2 (ja) 2013-03-14 2018-02-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としてのフロピリジン
SG11201506245QA (en) 2013-03-14 2015-09-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
BR112015032710A2 (pt) 2013-06-28 2017-07-25 Abbvie Inc inibidores de bromodomínio
RS63733B1 (sr) * 2013-10-18 2022-12-30 Celgene Quanticel Research Inc Inhibitori bromodomena
US9422281B2 (en) 2013-11-18 2016-08-23 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
SMT202100125T1 (it) 2013-11-18 2021-05-07 Forma Therapeutics Inc Composizioni di tetraidrochinolina come inibitori di bromodomini bet
US9988373B2 (en) 2013-12-26 2018-06-05 Shionogi & Co., Ltd. Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same
MY190835A (en) 2014-01-09 2022-05-12 Orion Corp Bicyclic heterrocyclic derivatives as bromodomain inhibitors
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
SG10201809353TA (en) 2014-04-23 2018-11-29 Incyte Corp 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
CR20170090A (es) 2014-09-12 2017-05-08 Glaxosmithkline Intellectual Property (No 2) Ltd Derivados de terahidroquinolina como inhibidores del bromodominio
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
EP3310772A1 (en) 2015-06-16 2018-04-25 Orion Corporation Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
CN108137585B (zh) 2015-09-21 2021-10-22 普莱希科公司 杂环化合物及其应用
JP6795588B2 (ja) 2015-09-22 2020-12-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
EP3374350B1 (en) 2015-11-09 2022-01-05 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
CA3007168A1 (en) 2015-12-14 2017-06-22 Zenith Epigenetics Ltd. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
EP3693369A3 (en) 2016-04-15 2020-09-09 AbbVie Inc. Bromodomain inhibitors
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
US11285218B2 (en) 2016-06-23 2022-03-29 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
CN110167939B (zh) 2017-01-11 2021-12-31 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
IL275478B2 (en) 2017-12-20 2024-06-01 Betta Pharmaceuticals Co Ltd A preparation that functions as a bromodomain protein inhibitor, and the composition
US11427593B2 (en) 2018-01-16 2022-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Bromodomain inhibitor compound and use thereof
CN110041253B (zh) 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
CN112424200B (zh) 2018-07-25 2022-09-20 正大天晴药业集团股份有限公司 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
WO2020063976A1 (zh) 2018-09-29 2020-04-02 如东凌达生物医药科技有限公司 一类稠杂环联芳基苄醇类化合物、制备方法和用途
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3967690A4 (en) 2019-03-17 2023-04-12 Shanghai Ringene BioPharma Co., Ltd. PYRROLAMIDOPYRIDONE COMPOUND, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
WO2020253711A1 (zh) 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
US11584756B2 (en) * 2019-07-02 2023-02-21 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
EP4143166A4 (en) 2020-04-29 2024-10-30 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS BET INHIBITORS

Also Published As

Publication number Publication date
JP7465945B2 (ja) 2024-04-11
CA3145827A1 (en) 2021-01-07
US11584756B2 (en) 2023-02-21
US20230339964A1 (en) 2023-10-26
CN114286818B (zh) 2024-09-20
JP2022538917A (ja) 2022-09-06
KR20220028072A (ko) 2022-03-08
WO2021003310A1 (en) 2021-01-07
EP3997070A4 (en) 2023-07-26
BR112021026668A2 (pt) 2022-02-15
AU2020299592A1 (en) 2022-02-17
IL289439B1 (en) 2025-12-01
CL2021003513A1 (es) 2022-10-28
CN114286818A (zh) 2022-04-05
KR102677015B1 (ko) 2024-06-19
IL289439A (en) 2022-02-01
EP3997070A1 (en) 2022-05-18
US20250276978A1 (en) 2025-09-04
US20210002293A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
JOP20210154B1 (ar) مثبطات kif18a
MX373154B (es) Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
CR20200518A (es) Piridozinonas como inhibidores de parp7
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
ZA202310316B (en) Fluoroalkyl-oxadiazoles and uses thereof
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EP3920923A4 (en) Therapeutic agents and methods of treatment
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
MX389256B (es) Compuestos heterociclicos y usos de los mismos.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201290103A1 (ru) Гетероциклические соединения и их использование
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX376047B (es) Inhibidores de desmetilasa-1 especifica de lisina.
PE20180258A1 (es) Inhibidores de bromodominio
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
EA201591823A1 (ru) Ингибиторы ido
MX386565B (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
BR112015029989A2 (pt) Uso de dianidrogalactitol e análogos e derivados do mesmo para tratar glioma maligno recorrente ou tumor cerebral secundário progressivo
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer